Loading organizations...
Polaris Genomics delivers an AI-powered genomic platform for biological clarity in mental health and neuropsychiatric conditions. Its ADAPT Neuropsychiatric Biomarker Discovery Platform integrates targeted gene panels with advanced analytics. This technology identifies biomarker signatures from liquid biopsy, enabling objective diagnostics and precision therapeutics.
Co-founded by Charles Cathlin, CEO, and Dr. Tshaka Cunningham, Director of Research & Development, the company began from the critical need for objective psychiatric biomarkers. Cathlin, an Air Force veteran with FDA experience, was driven by public health. Cunningham, a molecular biologist with a VA background, brought expertise in applying precision medicine.
Polaris Genomics serves researchers and developers in pharma, academia, and clinical settings. Leveraging genomics and machine learning, the company aims to accelerate drug discovery and improve individualized treatment efficacy. Its vision defines mental health's biological underpinnings, facilitating objective diagnostics and pioneering novel, biomarker-driven therapeutics.
Polaris Genomics has raised $2.0M across 1 funding round.
Polaris Genomics has raised $2.0M in total across 1 funding round.
Polaris Genomics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2020 | $2M Seed | — | Engineering Capital, Norwest Venture Partners, Wing Venture Capital, Sohaib Abbasi | Announced |
Polaris Genomics is a precision behavioral health technology company pioneering AI-powered genomics and machine learning to develop objective diagnostics and therapeutics for mental health conditions, particularly PTSD and neuropsychiatric disorders.[1][2][3][5] It offers products like the PTS-ID™ blood test for PTSD screening, the ADAPT Panel™ for gene network pathways in neuropsychiatric conditions, and the ADAPT Neuropsychiatric Biomarker Discovery Platform™, which analyzes blood-based biomarkers to support diagnostics, drug development, and clinical tools.[2][3][5] Serving researchers, pharma companies, clinicians, veterans, and the broader population affected by mental health crises, Polaris addresses the lack of biological objectivity in psychiatry—historically reliant on subjective assessments—by revealing "invisible wounds" through genomics, reducing stigma, and improving outcomes amid rising needs post-COVID.[1][3][5] The company, a Black-woman-veteran-owned business based in Gaithersburg, MD, has gained momentum via partnerships like Illumina Accelerator and Optum Genomics Clinical Catalyst Program, expanding from veteran-focused PTSD tools to universal mental health applications.[1][3]
Polaris Genomics was founded in 2017 by Charles Cathlin, MPH (CEO, 23-year US Air Force and Public Health Service veteran, Purple Heart recipient involved in 9/11 response) and Tshaka Cunningham, PhD (Chief Scientific Officer), inspired by their work at the Defense and Veterans Brain Injury Center and US Department of Veterans Affairs amid a crisis of 22 veteran suicides daily.[1][2][3] Drawing on expertise in biomedical technology, public health, and molecular biology, they partnered with the Illumina Accelerator, Mount Sinai, and Max Planck Institute of Psychiatry to create the first-to-market, patented TruGen-1 genomic biomarker assay (a 1003-gene panel for neuropsychiatric research) and PTS-ID™ for PTSD risk assessment via RNA expression in blood.[1][3][4] Initially focused on US military veterans with PTSD, the mission broadened in 2020 due to COVID-19's mental health fallout, evolving into a platform for all neuropsychiatric conditions while retaining veteran roots as a Black-woman-veteran-owned firm.[1][2]
Polaris rides the convergence of AI, genomics, and neuroscience, addressing psychiatry's biomarker void amid a global mental health epidemic—exacerbated by COVID, with PTSD affecting millions beyond veterans.[1][3][5] Timing aligns with advances in accessible sequencing (via Illumina ties) and demand for precision medicine, mirroring oncology's success in biomarker-driven therapies to de-risk neuropsychiatric drug development and lower healthcare costs.[3][5] Market forces like rising suicide rates, post-pandemic repercussions, and regulatory pushes for objective diagnostics favor Polaris, influencing the ecosystem by enabling pharma to shorten trials, equip clinicians with blood tests over questionnaires, and foster data repositories for AI-enhanced research—pioneering "biological clarity" in a field ripe for disruption.[2][5]
Polaris Genomics is poised to scale its ADAPT Platform for widespread biomarker adoption, potentially launching expanded PTS-ID™ commercially via Optum partnerships and pharma collaborations to target high-burden conditions like depression and anxiety.[3][5] Trends in AI-driven multi-omics, health equity mandates, and veteran-focused federal funding will propel growth, evolving its influence from niche PTSD innovator to ecosystem leader in stigma-free, biology-based mental health care. As the North Star guiding genomics in psychiatry, Polaris will illuminate paths to therapeutics that transform subjective suffering into measurable, treatable biology—fulfilling its founding vision for all.[1]
Polaris Genomics has raised $2.0M in total across 1 funding round.
Polaris Genomics's investors include Engineering Capital, Norwest Venture Partners, Wing Venture Capital, Sohaib Abbasi.